MVA-BN standard regimen + MVA-BN half-dose regimen
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Mpox (Monkeypox)
Conditions
Mpox (Monkeypox), Vaccination, Immunogenicity, Safety, Infants, Children
Trial Timeline
May 29, 2025 → Nov 1, 2026
NCT ID
NCT06844487About MVA-BN standard regimen + MVA-BN half-dose regimen
MVA-BN standard regimen + MVA-BN half-dose regimen is a phase 3 stage product being developed by Bavarian Nordic for Mpox (Monkeypox). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06844487. Target conditions include Mpox (Monkeypox), Vaccination, Immunogenicity.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06844487 | Phase 3 | Recruiting |
Competing Products
4 competing products in Mpox (Monkeypox)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BNT166a | BioNTech | Phase 2 | 49 |
| MVA-BN | Bavarian Nordic | Phase 2 | 49 |
| Jynneos + MVA-BN (Quail) | Bavarian Nordic | Phase 2 | 49 |
| Tecovirimat Oral Capsule + Placebo for Tecovirimat + Tecovirimat Oral Capsule (Open Label) | SIGA Technologies | Phase 3 | 69 |